Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome

Abstract EN

Schnitzler’s syndrome (SchS) is a rare, disabling, autoinflammatory disorder characterized by recurrent urticarial rash and monoclonal IgM gammopathy.

Interleukin-1 beta (IL-1β) plays an important role in the pathophysiology of SchS.

Only anecdotal reports demonstrate the efficiency and safety of human monoclonal anti-human IL-1β antibody (canakinumab) use in SchS therapy.

However, there are no generally accepted recommendations concerning the scheme (or frequency) of canakinumab use for this disease.

Here, we report the effective long-term treatment of SchS in a 44-year-old male with a standard canakinumab dose (150 mg) but with an increased 4-month injection interval.